US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma-PR Newswire APAC
- Written by PR Newswire Asia - Daily Bulletin Au RSS
SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of glioblastoma,...
Read more: US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma-PR Newswire APAC